Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)

          Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)November 29, 2024 6:00 PM EST | Source: Defence Therapeutics Inc.Vancouver, British Columbia--(Newsfile Corp. - November 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to ...